The Asian dermatologic patient: Review of common pigmentary disorders and cutaneous diseases

American Journal of Clinical Dermatology

Volumn 10, Issue 3, 2009, Pages 153-168

  Ho, Stephanie G Y ^a   Chan, Henry H L ^a,b,c,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FUDAN UNIVERSITY   (China)

^d 13/F Club Lusitano ^*  (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADAPALENE; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZELAIC ACID; BLEACHING AGENT; BOTULINUM TOXIN A; CALCIPOTRIOL; CHLORMETHINE; CLARITHROMYCIN; COLLAGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROMYCIN; ETRETIN; FLUOROURACIL; HYALURONIC ACID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; MELANIN; METHACRYLIC ACID METHYL ESTER; METHOTREXATE; PSORALEN; RETINOID; TACROLIMUS; TETRACYCLINE; TRIAMCINOLONE; UNINDEXED DRUG;

ACNE; AMYLOIDOSIS; ASIAN; ATOPIC DERMATITIS; ATROPHY; CHLOASMA; DIODE LASER; HUMAN; HYPERPIGMENTATION; HYPERTROPHIC SCAR; INFRARED RADIATION; INTENSE PULSED LIGHT; KELOID; LASER; LENTIGO; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEODYMIUM LASER; OTA NEVUS; PHOTOAGING; PHOTOTHERAPY; PHOTOTOXICITY; PIGMENT DISORDER; POSTINFLAMMATORY HYPERPIGMENTATION; PRIORITY JOURNAL; PSORIASIS; PULSED DYE LASER; RADIOFREQUENCY RADIATION; REVIEW; SKIN DISEASE; SWITCHED LASER; T CELL LYMPHOMA; TELANGIECTASIA;

ASIAN CONTINENTAL ANCESTRY GROUP; BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; HUMANS; PIGMENTATION DISORDERS; REJUVENATION; SKIN; SKIN DISEASES;

EID: 64849097054     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200910030-00002     Document Type: Review

References (125)

1. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: the 2006 revision [online]. Available from URL: http://www.un.org/esa/population/publications/wpp2006/ wpp2006.htm [Accessed 2007 Nov 27]
2. US Census Bureau, US Department of Commerce. US Census 2000. Washington, DC: US Census Bureau, Public Information Office, 2001 Sep
3. US Census Bureau News. Census bureau projects tripling of Hispanic and Asian populations in 50 years; non-Hispanic Whites may drop to half of total population. Washington, DC: Bureau of International Information Programs, U.S. Department of State, 2004 Mar 18
4. Chan HHL, Jackson B. Laser treatment on ethnic skin. In: Lim HW, Honigsmann H, Hawk JLM, editors. Photodermatology. New York: Informa Healthcare, 2007: 417-32
5. Szabo G. Pigment cell biology. In: Gordon M, editor. Mitochondria and other cytoplasmic inclusions. New York: Academic Press, 1959
6. Kaidbey KH, Agin PP, Sayre RM, et al. Photoprotection by melanin: a comparison of black and Caucasian skin. J Am Acad Dermatol 1979; 1: 249-60
7. Tadokoro T, Kobayashi N, Zmudzka BZ, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin and photosensitivity. FASEB J 2003; 17: 1177-9
8. Kotrajaras R, Kligman AM. The effect of topical tretinoin on photodamaged facial skin: the Thai experience. Br J Dermatol 1993; 129: 302-9
9. Griffiths CEM, Wang TS, Hamilton TA, et al. A photonumeric scale for the assessment of cutaneous photodamage. Arch Dermatol 1992; 128: 347-51
10. Larnier C, Ortonne JP, Venot A, et al. Evaluation of cutaneous photo-damage using a photographic scale. Br J Dermatol 1994; 130: 167-73
11. Chung JH. Photoaging in Asians. Photodermatol Photoimmunol Photomed 2003; 19: 109-21
12. Goh SH. The treatment of visible signs of senescence: the Asian experience. Br J Dermatol 1990; 122 Suppl. 35: 105-9
13. Chan HHL, Manstein D, Yu CS, et al. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med 2007; 39: 381-5
14. Chan HHL. Effective and safe use of lasers, light sources, and radio-frequency devices in the clinical management of Asian patients with selected dermatoses. Lasers Surg Med 2005; 37: 179-85
15. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995; 131: 1453-7
16. Kang WH, Yoon KH, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002; 146: 228-37
17. Grekin RC, Shelton RM, Geisse JK, etal. 510nm pigmented lesion dye laser: its characteristics and clinical uses. J Dermatol Surg Oncol 1993; 19: 380-7
18. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994; 20: 592-7
19. Negishi K, Kushikata N, Tezuka Y, et al. Study of the incidence and nature of "very subtle epidermal melasma" in relation to intense pulsed light treatment. Dermatol Surg 2004; 30: 881-6
20. Wang CC, Hui CY, Sue YM, et al. Intense pulsed light for the treatment of refractory melasma in Asian patients. Dermatol Surg 2004; 30: 1196-200
21. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698-710
22. Griffiths CEM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 1993; 129: 415-21
23. Sarkar R, Kaur C, Bhalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 2002; 28: 828-32
24. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25: 18-22
25. Yoshimura K, Harii K, Aoyama T, et al. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg 2000; 105: 1097-8
26. Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25: 121-3
27. Angsuwarangsee S, Polnikorn N. Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design. Dermatol Surg 2003; 29:59-64
28. Nouri K, Bowes L, Chartier T, et al. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999; 25: 494-7
29. Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg 2005; 31: 1645-50
30. Wang CC, Sue YM, Yang CH, et al. A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: a randomised, physician-blinded, split-face comparative trial. J Am Acad Dermatol 2006; 54: 804-10
31. Anderson RR, Margolis RJ, Watenabe S. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd:YAG laser pulses at 1064, 532 and 355 nm. J Invest Dermatol 1989; 93: 28-32
32. Murphy MJ, Huang MY. Q-switched ruby laser treatment of benign pigmented lesions in Chinese skin. Am Acad Med Singapore 1994; 23:60-6
33. Chan HH, Fung WKK, Ying SY, et al. An in vivo trial comparing the use of different types of 532 nm Nd:YAG lasers in the treatment of facial lenti-gines in oriental patients. Derm Surg 2000; 26 (8): 743-9
34. Ara G, Anderson RR, Mandel KG, et al. Irradiation of pigmented melanoma cells with high intensity pulsed radiation generates acoustic waves and kill cells. Lasers Surg Med 1990; 10: 52-9
35. Negishi K, Tezuka Y, Kushikata N, et al. Photorejuvenation for Asian skin by intense pulsed light. Dermatol Surg 2001; 27: 627-32
36. Chan HH. The use of lasers and intense pulsed light sources for the treatment of acquired pigmentary lesions in Asians. J Cosmet Laser Ther 2003; 5:198-200
37. Negishi K, Wakamatsu S, Kushikata N, et al. Full-face photorejuvenation of photodamaged skin by intense pulsed light with integrated contact cooling: initial experiences in Asian patients. Lasers Surg Med 2002; 30:298-305
38. Kawada A, Shiraishi H, Asai M, et al. Clinical improvement of solar lentigines and ephelides with an intense pulsed light source. Dermatol Surg 2002; 28: 504-8
39. Kono T, Manstein D, Chan HH, et al. Q-switched ruby vs. long-pulsed dye laser delivered with compression for treatment of facial lentigines in Asians. Lasers Surg Med 2006; 38: 94-7
40. Hidano A, Kajama H, Ikeda S, et al. Natural history of nevus of Ota. Arch Dermatol 1967; 95: 187-95
41. Chan HH, Alam M, Kono T, et al. Clinical application of lasers in Asians. Dermatol Surg 2002; 28: 556-63
42. Watanabe S, Takahashi H. Treatment of nevus of Ota with the Q-switched ruby laser. New Engl J Med 1994; 331: 1745-50
43. Kono T, Nozaki M, Chan HH, et al. A retrospective study looking at the long-term complicationsofQ-switched ruby laserinthe treatment of nevus of Ota. Lasers Surg Med 2001; 29: 156-9
44. Chan HH, King WWK, Chan ESY, et al. An in vivo trial comparing the patients' tolerability of Q-switched alexandrite and Q-switched neodymium:yttrium-aluminium-garnet lasers in the treatment of nevus of Ota. Lasers Surg Med 1999; 24: 24-8
45. Chan HH, Ying SY, Ho WS, et al. An in vivo trial comparing the clinical efficacy and complications of Q-switched 755nm alexandrite and Q-switched 1064 nm Nd:YAG lasers in the treatment of nevus of Ota. Dermatol Surg 2000; 26: 919-22
46. Hori Y, Kawashima M, Oohara K, et al. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984; 10: 961-4
47. Hori Y, Takayama O. Circumscribed dermal melanoses: classification and histologic features. Dermatol Clin 1988; 6: 315-26
48. Kunachak S, Leelaudomlipi P, Sirikulchayanonta V. Q-switched ruby laser therapy of acquired bilateral nevus of Ota-like macules. Dermatol Surg 1999; 25: 938-41
49. Lam AY, Wong DS, Lam LK, etal.A retrospective study on the efficacy and complications of Q-switched alexandrite laser in the treatment of acquired bilateral nevus of Ota-like macules. Dermatol Surg 2001; 27: 937-41
50. Polnikorn N, Tanrattanakorn S, Goldberg DJ. Treatment of Hori's nevus with the Q-switched Nd:YAG laser. Dermatol Surg 2000; 26: 477-80
51. Ee HL, Goh CL, Khoo LS, et al. Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) with a combination of the 532 nm Q-switched Nd:YAG followed by the 1064 nm Q-switched Nd:YAG is more effective: prospective study. Dermatol Surg 2006; 32: 34-40
52. Hse TS, Zelickson B, Dover JS, et al. Multicenter study of the safety and efficacy of a 585nmpulsed-dye laser for the nonablative treatment of facial rhytides. Dermatol Surg 2005; 31: 1-9
53. Trelles MA, Allones I, Levy JL, et al. Combined nonablative skin rejuvenation with the 595- and 1450-nm lasers. Dermatol Surg 2004; 30: 1292-8
54. Fitzpatrick R, Geronemus RG, Goldberg D, et al. Multicenter study of non-invasive radiofrequency for periorbital tissue tightening. Lasers Surg Med 2003; 33: 232-42
55. Kushikata N, Negishi K, Tezuka Y, et al. Non-ablative skin tightening with radiofrequency in Asian skin. Lasers Surg Med 2005; 36: 92-7
56. Dover JS, Zelickson B, 14-Physician Multispecialty Consensus Panel. Results of a survey of 5,700 patient monopolar radiofrequency facial skin tightening treatments: assessment of a low-energy multiple-pass technique leading to a clinical end point algorithm. Derm Surg 2007 May; 33 (8): 900-7
57. Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the National Skin Centre (Singapore) from 1989-1990. Int J Dermatol 1992; 31: 555-9
58. Mar A, Tam A, Jolley D, et al. The cumulative incidence of atopic dermatitis in the first 12 months among Chinese, Vietnamese, and Caucasian infants born in Melbourne, Australia. J Am Acad Dermatol 1999; 40: 597-602
59. Worth R. Atopic dermatitis among Chinese infants in Honolulu and San Francisco. Hawaii Med J 1962; 22: 31-4
60. George S, Berth-Jones J, Graham-Brown R. A possible explanation for the increased referral of atopic dermatitis from the Asian community in Leicester. Br J Dermatol 1997; 136: 494-7
61. Levy ML. Atopic dermatitis: understanding the disease and its management. Curr Med Res Opin 2007 Dec; 23 (12): 3091-103
62. Yeung CK, Teo LHY, Xiang LH, etal. Acommunity-based epidemiological study of acne vulgaris in Hong Kong adolescents. Acta Derm Venereol 2002; 82: 104-7
63. Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. J Am Acad Dermatol 2002; 46 (2 Suppl.): S98-106
64. Jeong JT, Park JH, Kye YC. Resurfacing of pitted facial acne scars using Er:YAG laser with ablation and coagulation mode. Aesthetic Plast Surg 2003; 27: 130-4
65. Wala S, Alster TS. Prolonged clinical and histological effects from CO2 laser resurfacing of atrophic acne scars. Dermatol Surg 1999; 25: 926-30
66. Goh CL, Khoo L. Laser skin resurfacing treatment outcome of facial scars and wrinkles in Asians with skin type III/IV with the Unipulse CO2 laser system. Singapore Med J 2002; 43: 28-32
67. Ashkenazi H, Malik Z, Harth Y, et al. Eradication of Proprionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol 2003; 35: 17-24
68. Seaton ED, Charakida A, Mouser PE, et al. Pulsed-dye laser treatment for inflammatory acne vulgaris: randomised controlled trial. Lancet 2003; 362: 1347-52
69. Orringer JS, Kang S, Hamilton T, et al. Treatment of acne vulgaris with a pulsed dye laser:arandomized controlled trial. JAMA 2004; 291 (23): 2834-9
70. Goldman MP, Boyce SM. A single-center study of aminolevulinic acid and 417nm photodynamic therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol 2003; 2: 393-6
71. Alexiades-Armenakas M. Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild to severe comedonal, inflammatory, or cystic acne. J Drugs Dermatol 2006; 5: 45-55
72. Hongcharu W, Taylor CR, Chang Y, et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000 Aug; 115 (2): 183-92
73. Chua SH, Ang P, Khoo LSW, et al. Nonablative 1450 nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg 2004; 30 (10): 1287-91
74. Bernstein EF. A pilot investigation comparing low-energy, double pass 1,450nm laser treatment of acne to conventional single-pass, high-energy treatment. Lasers Surg Med 2007; 39 (2): 193-8
75. Kono T, Chan HHL, Groff WF, et al. Prospective direct comparison study of fractional resurfacing using different fluences and densities for skin rejuvenation in Asians. Lasers Surg Med 2007; 39 (4): 311-4
76. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46 (2 Suppl.): S63-97
77. Reed BR, Clark RA. Cutaneous tissue repair: practical implications of current knowledge: II. J Am Acad Dermatol 1985; 13: 919-41
78. Ketchum LD, Cohen IK, Masters FW. Hypertrophic scars and keloids: a collective review. Plast Reconstr Surg 1974; 53: 140-54
79. Friedman SJ, Butler DR, Dittelkov MR. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. J Am Acad Dermatol 1988; 19: 537-41
80. Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999; 25: 224-32
81. Goldman MP, Fitzpatrick RE. Laser treatment of scars. Dermatol Surg 1995; 21: 685-7
82. Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345: 1198-200
83. Manuskiatti W, Fitzpatrick RE, Goldman MP. Energy density and numbers of treatment affect response of keloidal and hypertrophic scars to the 585-nm flashlamp-pumped pulsed-dye laser. J Am Acad Dermatol 2001; 45 (4): 557-65
84. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138 (9): 1149-55
85. Chan HH, Wong DS, Ho WS, et al. The use of pulsed dye laser for the prevention and treatment of hypertrophic scarsin Chinese. Dermatol Surg 2004; 30: 987-94
86. Lupton JR, Alster TS. Laser scar revision. Dermatol Clin 2002; 20: 55-65
87. Farber E, Grauer F, Zaruba F. Racial incidence of psoriasis. Cesk Dermatol 1965; 40: 289-97
88. Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol 2005; 44: 1016-21
89. Wong C. Cutaneous amyloidosis. Int J Dermatol 1987; 26: 273-7
90. Wang WJ, Chang YT, Huang CY, et al. Clinical and histopathological characteristics of primary cutaneous amyloidosis in 794 Chinese patients. Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64 (2): 101-7
91. Lee CS, Lim HW. Cutaneous diseases in Asians. Dermatol Clin 2003; 21: 669-77
92. Wang W, Huang C, Chang Y, et al. Anosacral cutaneous amyloidosis: a study of 10 Chinese cases. Br J Dermatol 2000; 143: 1266-9
93. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol 1988 Jan; 18: 1-16
94. Juan CC, Hwang B, Lee PC, et al. The clinical manifestations and risk factors of a delayed diagnosis of Kawasaki disease. J Chin Med Assoc 2007; 70 (9): 374-9
95. Dean A, Melish M, Hicks R, et al. An epidemic of Kawasaki syndrome in Hawaii. J Pediatr 1982; 100: 552-7
96. Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep 2002 Feb; 4 (1): 25-9
97. Jemal A, Devesa SS, Hartge P, et al. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001; 93: 678-83
98. Koh D, Wang H, Lee J, et al. Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry Data 1968-1997. Br J Dermatol 2003; 148: 1161-6
99. Waterhouse J, Correa P, Muir C, et al., editors. Cancer incidence in five continents: vol. 4. Lyon: International Agency for Research in Cancer, 1976
100. Ishihara K, Saida T, Yamamoto A. Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol 2001; 6: 109-16
101. Collins RJ. Melanoma in the Chinese of Hong Kong: emphasis on volar and subungual sites. Cancer 1984; 54: 1482-8
102. Byrd KM, Wilson DC, Hoyler SS. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol 2004; 50: 142-3
103. Kikuchi A, Shimizu H, Nishikawa T. Clinical and histopathological characteristics of basal cell carcinoma in Japanese patients. Arch Dermatol 1996; 132: 320-4
104. Chuang T, Reizner GT, Elpern DJ, et al. Nonmelanoma skin cancer in Japanese ethnic Hawaiians in Kauai, Hawaii: an incidence report. J Am Acad Dermatol 1995; 33: 422-6
105. Ichihashi M, Naruse K, Harada S, et al. Trends in nonmelanoma skin cancer in Japan. Recent Results Cancer Res 1995; 139: 263-73
106. Gloster HM, Neal K.Skin cancer inskinof color. JAmAcad Dermatol 2006 Nov; 55: 741-60
107. Stone MC, Styles AR, Cockerell CJ. Hypopigmented mycosis fungoides: a report of 7 cases and review of the literature. Cutis 2001; 67: 133-8
108. Lambroza E, Cohen SR, Phelps R, et al. Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol 1995; 32: 987-93
109. Akaraphanth R, Douglass MC, Lim HW. Hypopigmented mycosis fungoides: treatment and a 6(1/2) year follow-up of 9 patients. J Am Acad Dermatol 2000; 42: 33-9
110. Blitzer A, Brin MF, Keen MS, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993; 119 (9): 1018-22
111. Anh KY, Park MY, Park DH, et al. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg 2000; 105 (2): 778-84
112. Carruthers A, Carruthers JDA. The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol 1997; 7: 11-5
113. Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001; 27 (8): 703-8
114. Kim NH, Chung JH, Park RH, et al. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg 2005; 115 (3): 919-30
115. Lee HJ, Lee DW, Park YH, etal. Botulinum toxin A for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg 2004; 30 (6): 867-71
116. Han KH, Joo YH, Moon SE, et al. Botulinum toxin A treatment for contouring of the lower leg. J Dermatolog Treat 2006; 17 (4): 250-4
117. Klein AW. In favour of double testing. J Dermatol Surg Oncol 1989; 15: 263
118. Narins RS, BrandtF, Leyden J, etal. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29: 588-95
119. Lowe NJ, Maxwell A, Lowe P, et al. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol 2001; 45: 930-3
120. Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces Restylane-mediated cutaneous augmentation. Arch Fac Plast Surg 2005; 7: 231-7
121. Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material. Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 2004; 114 (4): 964-76
122. Lemperle G, Romano JJ, Busso M. Soft tissue augmentation with Artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 2003; 29: 573-87
123. Carruthers A, Carruthers JDA. Polymethylmethacrylate microspheres/ collagen as a tissue augmenting agent: personal experience over 5 years. Dermatol Surg 2005; 31: 1561-5
124. Arnaud P, Saint-Marc T, Katz P. The effects of polylactic acid (PLA) [New-Fill] as therapy for lipoatrophy of the face [abstract]. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2000 Sep 13-15; Toronto (ON)
125. Beljaards RC, deRoos K,BruinsFG. New-Fill for skin augmentation: a new filler or failure? Dermatol Surg 2005; 31: 772-6